Featured Editorial

  1. Demonstrating Non-Inferiority Of BFPCs Vs. Traditional Air Monitoring 7/22/2026

    Demonstrating non-inferiority of bio-fluorescent particle counter (BFPC) technology to traditional active air-sampling methods is essential for implementation. Here's how to approach it.

  2. Multispecific Manufacturability Starts With Molecular Design 7/21/2026

    AP Biosciences’ VP of antibody discovery, Jhong-Jhe You, Ph.D., explains the key design elements of multispecific antibodies and how they affect product developability.

  3. The Missing Layer: Why CAR-T Needs AI As Its Connective Tissue 7/21/2026

    AI can close CAR-T’s access gap by replacing fragmented community delivery handoffs with automated orchestration across referral, reimbursement, logistics, and monitoring.

  4. Building A Self-Driving Lab For LNP Development 7/20/2026

    With commercially available components, MIT researchers built a platform that accelerates LNP process development, optimization, and autonomous manufacturing research.

  5. Exploring Takeda's Template For Sustainable Steam Generation 7/17/2026

    Takeda designed a model for delivering steam at 11 bar and up to 184 degrees using natural refrigerant and waste heat at one of its largest production sites.

  6. Addressing The Particulate Challenge In Cell Therapy Products 7/15/2026

    Cell therapy products challenge traditional particulate controls. One expert explains detection, mitigation, and contamination prevention.

  7. Let's Stop Treating Allogeneic Cell Therapy As One Thing 7/14/2026

    Industry is beginning to accept that allogeneic cell therapy spans categories, and success depends on aligning biology, regulation, and economics unique to each product.

  8. Allogeneic Cell Therapy Is Still Learning What Biology Will Allow 7/14/2026

    Allogeneic cell therapy is advancing through smarter donor selection and manufacturing control, showing how biology, process design, and product consistency drive success.

  9. On The Ground At BIO 2026: Johanna Kaufmann, Ph.D., On The Oncology Modality Puzzle 7/10/2026

    At the 2026 BIO International Convention, Bioprocess Online caught up with Johanna Kaufmann, Ph.D., CSO at Deck Bio, a company developing multi-targeted T-cell engagers for solid tumors.

  10. BIO 2026: Modernizing The FDA And Bolstering The Workforce 7/10/2026

    Bioprocess Online's chief editor, Tyler Menichiello, shares his key takeaways from the 2026 BIO International Convention in San Diego.